ACYCLOVIR PROPHYLAXIS OF HERPES-SIMPLEX-VIRUS INFECTIONS - A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL IN BONE-MARROW-TRANSPLANT RECIPIENTS
ACYCLOVIR PROPHYLAXIS OF HERPES-SIMPLEX-VIRUS INFECTIONS - A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL IN BONE-MARROW-TRANSPLANT RECIPIENTS
复制标题
DOI：
10.1056/nejm198107093050202
复制
发表时间：
1981-01-01
影响因子：
158.5
通讯作者：
LIETMAN, PS
中科院分区：
文献类型：
--
作者：
SARAL, R;BURNS, WH;LIETMAN, PS
对20例血清学阳性骨髓移植受者进行了无环鸟苷预防单纯疱疹病毒（HSV）感染的双盲、安慰剂对照研究。从移植前3天开始，给予阿昔洛韦或安慰剂18天。在研究期间，10名接受安慰剂的患者中有7名出现培养阳性HSV病变，但10名接受阿昔洛韦的患者中没有出现这种病变（P. simeq. 0.003）。所有患者均无药物毒性证据。5例接受阿昔洛韦治疗的患者在停药后出现轻度培养阳性HSV感染，另外2例患者在没有病变的情况下脱落病毒。阿昔洛韦似乎是一种有效的HSV复制抑制剂。虽然无环鸟苷似乎不能根除潜伏感染，但它可以有效预防再活化感染。
A double-blind, placebo-controlled study of acyclovir prophylaxis agains infection with herpes simplex virus (HSV) in 20 seropositive recipients of bone-marrow transplants was conducted. Acyclovir or placebo was administered for 18 days, starting 3 days before transplantation. Culture-positive HSV lesions developed during the study in 7 of the 10 patients who received placebo, but no such lesions appeared in the 10 patients who received acyclovir (P .simeq. 0.003). None of the patients had evidence of drug toxicity. Five of the patients treated with acyclovir had mild culture-positive HSV infections after cessation of the drug and 2 additional patients shed virus without having lesions. Acyclovir appears to be a potent inhibitor of HSV replication. Although acyclovir does not appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections.